SG10201809280PA - Combination of brexpiprazole and nalmefene and use thereof for treating substance-related disorders - Google Patents

Combination of brexpiprazole and nalmefene and use thereof for treating substance-related disorders

Info

Publication number
SG10201809280PA
SG10201809280PA SG10201809280PA SG10201809280PA SG10201809280PA SG 10201809280P A SG10201809280P A SG 10201809280PA SG 10201809280P A SG10201809280P A SG 10201809280PA SG 10201809280P A SG10201809280P A SG 10201809280PA SG 10201809280P A SG10201809280P A SG 10201809280PA
Authority
SG
Singapore
Prior art keywords
brexpiprazole
nalmefene
combination
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
SG10201809280PA
Inventor
Kenji Maeda
Mai Nakamura
Original Assignee
Otsuka Pharma Co Ltd
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53191808&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201809280P(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Otsuka Pharma Co Ltd, H Lundbeck As filed Critical Otsuka Pharma Co Ltd
Publication of SG10201809280PA publication Critical patent/SG10201809280PA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Addiction (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

COMBINATION OF BREXPIPRAZOLE AND NALMEFENE AND USE THEREOF FOR TREATING SUBSTANCE-RELATED DISORDERS A medicament comprising (I) brexpiprazole or a pharmaceutically acceptable salt thereof, and (II) nalmefene or 5 a pharmaceutically acceptable salt thereof in combination, wherein brexpiprazole or a pharmaceutically acceptable salt thereof, and nalmefene or a pharmaceutically acceptable salt thereof are contained in a single preparation, or a pharmaceutical composition containing brexpiprazole or a 10 pharmaceutically acceptable salt thereof and a pharmaceutical composition containing nalmefene or a pharmaceutically acceptable salt thereof are formulated for use in combination. The medicament is used for the prophylaxis or treatment of a substance-related disorder, preferably an alcohol-related 15 disorder. (No drawing to be published)
SG10201809280PA 2014-04-22 2015-04-22 Combination of brexpiprazole and nalmefene and use thereof for treating substance-related disorders SG10201809280PA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2014088148 2014-04-22

Publications (1)

Publication Number Publication Date
SG10201809280PA true SG10201809280PA (en) 2018-11-29

Family

ID=53191808

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201608766TA SG11201608766TA (en) 2014-04-22 2015-04-22 Combination of brexpiprazole and nalmefene and use thereof for treating substance-related disorders
SG10201809280PA SG10201809280PA (en) 2014-04-22 2015-04-22 Combination of brexpiprazole and nalmefene and use thereof for treating substance-related disorders

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201608766TA SG11201608766TA (en) 2014-04-22 2015-04-22 Combination of brexpiprazole and nalmefene and use thereof for treating substance-related disorders

Country Status (18)

Country Link
US (3) US20170042887A1 (en)
EP (1) EP3134090B1 (en)
JP (1) JP6797691B2 (en)
KR (1) KR20160138301A (en)
CN (1) CN106456634A (en)
AR (1) AR100153A1 (en)
AU (1) AU2015250611A1 (en)
BR (1) BR112016024510A2 (en)
CA (1) CA2946698A1 (en)
CL (1) CL2016002653A1 (en)
ES (1) ES2742888T3 (en)
IL (1) IL248381A0 (en)
MX (1) MX2016013889A (en)
PH (1) PH12016502107A1 (en)
RU (1) RU2016145411A (en)
SG (2) SG11201608766TA (en)
TW (1) TW201625252A (en)
WO (1) WO2015163486A1 (en)

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3814768A (en) 1971-11-26 1974-06-04 Lewenstein E 6-methylene-6-desoxy dihydro morphine and codeine derivatives and pharmaceutically acceptable salts
US4535157A (en) 1983-11-01 1985-08-13 Key Pharmaceuticals, Inc. Process for making 6-desoxy-6-methylenenaloxone and 6-desoxy-6-methylenenaltrexone
US4751307A (en) 1985-01-17 1988-06-14 Mallinckrodt, Inc. Wittig-reaction processes
US5086058A (en) * 1990-06-04 1992-02-04 Alko Ltd. Method for treating alcoholism with nalmefene
US20060235038A1 (en) * 1996-05-06 2006-10-19 Simon David L Novel therapeutic uses for nalmefene
JP2002508753A (en) * 1997-05-20 2002-03-19 エール ユニバーシティ Drug dependent treatment using opiate antagonists and serotonin compounds
AR031682A1 (en) 1999-11-19 2003-10-01 Reckitt Benckiser Helthcare Uk PHARMACEUTICAL COMPOSITIONS
US7923454B2 (en) 2002-05-17 2011-04-12 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
UA83504C2 (en) * 2003-09-04 2008-07-25 Селджин Корпорейшн Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
US20050245541A1 (en) 2004-03-19 2005-11-03 Elliot Ehrich Methods for treating alcoholism
TWI320783B (en) 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
US20070179168A1 (en) 2005-11-28 2007-08-02 Orexigen Therapeutics, Inc. Methods of treating anxiety disorders
JP4540700B2 (en) 2006-10-13 2010-09-08 大塚製薬株式会社 Medicine
US20100168119A1 (en) * 2008-11-05 2010-07-01 Pharmorx, Inc. Compositions and methods for minimizing or reducing agonist-induced desensitization
UA102128C2 (en) 2008-12-05 2013-06-10 Х. Луннбек А/С Nalmefene hydrochloride dihydrate
CA2763093C (en) 2009-05-25 2017-03-07 Carla De Faveri Preparation of nalmefene hydrochloride from naltrexone
JP6246589B2 (en) 2010-11-05 2017-12-13 ハー・ルンドベック・アクチエゼルスカベット Method for producing naltrexone
JOP20120083B1 (en) 2011-04-05 2021-08-17 Otsuka Pharma Co Ltd Combinations comprising brexpiprazole or a salt thereof and a second drug for use in the treatment of a cns disorder
TWI562991B (en) 2012-04-23 2016-12-21 Otsuka Pharma Co Ltd Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same
US20140005217A1 (en) 2012-06-27 2014-01-02 H. Lundbeck A/S Nalmefene for reduction of alcohol consumption in specific target populations
JOP20210047A1 (en) * 2012-10-25 2017-06-16 Otsuka Pharma Co Ltd Prophylactic and/or therapeutic agent for behavioral and psychological symptoms associated with neurodegenerative disease or impulsive symptoms associated with mental disease containing brexpiprazole or salt thereof
JP2014088148A (en) 2012-10-31 2014-05-15 Daihatsu Motor Co Ltd Vehicle body structure
JP6406713B2 (en) * 2013-01-30 2018-10-17 ファーモレックス セラピューティクス， インコーポレイテッド Treatment of depression and other diseases with low dose drugs

Also Published As

Publication number Publication date
EP3134090B1 (en) 2019-06-05
ES2742888T3 (en) 2020-02-17
JP6797691B2 (en) 2020-12-09
US20200368227A1 (en) 2020-11-26
BR112016024510A2 (en) 2017-08-15
RU2016145411A3 (en) 2018-10-03
IL248381A0 (en) 2016-11-30
JP2017513895A (en) 2017-06-01
WO2015163486A1 (en) 2015-10-29
EP3134090A1 (en) 2017-03-01
US20170042887A1 (en) 2017-02-16
AU2015250611A1 (en) 2016-11-24
SG11201608766TA (en) 2016-11-29
KR20160138301A (en) 2016-12-02
CA2946698A1 (en) 2015-10-29
RU2016145411A (en) 2018-05-23
TW201625252A (en) 2016-07-16
CL2016002653A1 (en) 2017-04-21
CN106456634A (en) 2017-02-22
AR100153A1 (en) 2016-09-14
MX2016013889A (en) 2017-03-09
US20190151309A1 (en) 2019-05-23
US11642341B2 (en) 2023-05-09
PH12016502107A1 (en) 2017-01-09

Similar Documents

Publication Publication Date Title
SG10201808102WA (en) Bicyclic heterocycle compounds and their uses in therapy
EP4282479A3 (en) Use of pridopidine to treat depression or anxiety
SG10201808104RA (en) Cenicriviroc for the treatment of fibrosis
MX365939B (en) Nuclear transport modulators and uses thereof.
MX2016012574A (en) Substituted heteroaryl compounds and methods of use.
MX2016015434A (en) Pharmaceutical combinations for treating cancer.
PH12016502352A1 (en) Pharmaceutical composition
MX2021002321A (en) Novel methods.
TW201613578A (en) Pharmaceutical combinations
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
EA032271B9 (en) Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases
MX2018008645A (en) 8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives.
ZA201805358B (en) 3-(carboxymethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
MX2018004220A (en) Pyrazolyl substituted tetrahydropyranylsulfones.
MX2021002322A (en) Novel methods.
NZ745187A (en) 3-(carboxyethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
EA201692111A1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING DANIRYXIN FOR TREATING INFECTIOUS DISEASES
MX2018008643A (en) 3-((hetero-)aryl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives.
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
MX2018004217A (en) Pyrazolyl substituted tetrahydropyranylsulfones.
PH12016502480A1 (en) Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases
SG10201809280PA (en) Combination of brexpiprazole and nalmefene and use thereof for treating substance-related disorders
MX2018006631A (en) Compound for use in the prevention and treatment of neurodegenerative diseases.
UA108139U (en) METHOD OF CIRCLE THERAPY WITH ENDOMETRITIS AS PREVENTION OF GONADOPATHY
MX2016010919A (en) 4-benzylsulfonyl-2-butenenitrile.